Search
Statistics
We have 222 registered usersThe newest registered user is raheelmemon
Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
BRITE-MD Trial: Quantitative EEG Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psychiatry In Depth
Page 1 of 1
BRITE-MD Trial: Quantitative EEG Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression
Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression:
A Report From the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) Trial
A Report From the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) Trial
Source: J Clin Psychiatry 2013;74(1):51–56
Clinical trials in major depressive disorder (MDD) commonly assess remission at a single endpoint. Complementary, clinically relevant metrics include the likelihood and speed of achieving sustained remission. A neurophysiologic measure, the Antidepressant Treatment Response (ATR) index, previously predicted 8-week outcomes of pharmacotherapy. We retrospectively examined data from the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) trial to evaluate this biomarker’s properties in predicting sustained remission and time to achieve sustained remission.
Method: In the BRITE-MD trial, 67 adults with DSM-IV MDD received escitalopram continuously for 13 weeks. The 17-item Hamilton Depression Rating Scale (HDRS17) was used to define sustained remission as achieving remission (HDRS17 score ≤ 7) at a series of consecutive assessments, including week 13. The onset of sustained remission was defined as the earliest time from which all subsequent HDRS17 assessments were ≤ 7. The ATR was evaluated by using frontal quantitative electroencephalogram recordings at baseline and week 1. Subjects were stratified based on ATR status (ie, ATR+/ATR−). Kaplan-Meier survival analysis evaluated group differences in time to sustained remission. Higher ATR was hypothesized to predict sustained remission and time to sustained remission. Subjects participated between January 2006 and July 2007.
Results:
- Of 67 subjects, 36 achieved remission by week 13, and ATR predicted this single endpoint in receiver operating characteristic analyses (P = .016; sensitivity, 52.8%; positive predictive value, 76.0%). Remitters had a higher mean (SD) ATR value than those who did not remit (57.9 [10.0] vs 51.9 [8.7], P = .012).
- 16 of the 31 individuals with sustained remission had ATR+ status, while 28 of the 36 who were not sustained remitters had ATR– status (P = .012).
- The mean time to reach sustained remission was significantly shorter among ATR+ subjects than ATR– individuals (38 vs 53 days, P = .038).
Conclusions: The ATR index predicted remission at 13 weeks as well as the speed of achieving sustained remission with antidepressant monotherapy. This finding suggests that the ATR biomarker may predict stable longer-term outcomes.
Similar topics
» "REMIT 5" Useful for Evaluating Depression Remission
» TNF Antagonist Infliximab for Treatment-Resistant Depression: The Role of Baseline Inflammatory Biomarkers
» Possible reason for Major Depression: Problem with Working Memory
» Predicting Treatment Response in Social Anxiety Disorder From Functional MRI
» Combination Antidepressant Therapy May Not Improve Odds of Remission Among Chronically Depressed
» TNF Antagonist Infliximab for Treatment-Resistant Depression: The Role of Baseline Inflammatory Biomarkers
» Possible reason for Major Depression: Problem with Working Memory
» Predicting Treatment Response in Social Anxiety Disorder From Functional MRI
» Combination Antidepressant Therapy May Not Improve Odds of Remission Among Chronically Depressed
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psychiatry In Depth
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Sep 10, 2016 1:45 pm by Admin
» L-Methylfolate: Who Will benefit
Sat Sep 03, 2016 3:00 pm by Admin
» Vitamins & Supplements in Clinical Practice.
Sun Aug 21, 2016 12:27 pm by Admin
» Imaging Biomarkers for Outcomes in Mild TBI
Fri Jul 22, 2016 12:37 pm by Admin
» Q.5 Clozapine Neutopenia
Mon Jul 11, 2016 8:43 pm by Admin
» Treating Disorders!
Mon Jul 04, 2016 1:52 am by troymackys
» Cortical Abnormalities in Adults & Adolescents with MDD
Sun Jul 03, 2016 12:59 pm by Admin
» Efficacy of Antipsychotics in Pediatric Acute Mania
Wed Jun 22, 2016 8:46 pm by Admin
» Obsessive Compulsive Disorder in Adults: Which Treatment is Better?
Tue Jun 21, 2016 9:34 pm by Admin